Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LENALIDOMIDE vs ADDERALL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Multiple myeloma (in combination with dexamethasone),Myelodysplastic syndromes associated with deletion 5q,Mantle cell lymphoma (relapsed or refractory)
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
Terminal half-life ~3 hours (range 2-5 h) in multiple myeloma patients; prolongation in renal impairment requires dose adjustment.
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
Metabolized via hydrolysis and glucuronidation; CYP450 enzymes play a minor role.
Amphetamine is metabolized primarily by hepatic CYP2D6 and to a lesser extent by CYP2C19 and CYP2C9, with some minor pathways involving dopamine beta-hydroxylase.
Renal: ~82% unchanged; fecal <5%; biliary negligible.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
~30% bound, primarily to albumin.
~16-20%; primarily binds to albumin, with minor binding to alpha-1-acid glycoprotein.
Approximately 0.6 L/kg (range 0.4-0.8 L/kg), indicating distribution into total body water.
Vd: 3.0-4.5 L/kg (range 2.6-5.6); indicates extensive tissue distribution, including brain, with accumulation in kidneys and liver.
Oral: ~80% (range 60-100%); food does not significantly affect absorption.
Oral: ~76% (range 64-95%) for mixed amphetamine salts; bioavailability reduced by acidic gastric p H and increased with food (Tmax delayed but AUC unchanged).
For Cr Cl 30-60 m L/min: 5 mg once daily; for Cr Cl <30 m L/min not requiring dialysis: 2.5 mg once daily; for Cr Cl <30 m L/min requiring dialysis: 2.5 mg once daily post-dialysis on dialysis days.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: contraindicated.
No specific dose adjustment for hepatic impairment in FDA labeling; use with caution in severe hepatic impairment (Child-Pugh C) due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not approved in pediatric patients; safety and efficacy not established in patients <18 years.
Weight-based: <50 kg: 2.5-5 mg once daily; 50-100 kg: 5-10 mg once daily; >100 kg: adult dosing.
No specific dose adjustment beyond renal function; monitor for hematologic toxicity and thromboembolic events due to age-related comorbidities and renal impairment.
Start at 2.5-5 mg once daily; increase slowly due to increased sensitivity and cardiovascular risk.
Embryo-fetal toxicity: Can cause fetal harm. Do not use during pregnancy. Females of reproductive potential must use contraception or abstain. Hematologic toxicity: Significant neutropenia and thrombocytopenia; monitor blood counts. Deep vein thrombosis and pulmonary embolism: Increased risk; monitor and consider prophylaxis.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence throughout therapy.
Hematologic toxicity (neutropenia and thrombocytopenia); thromboembolic events; hepatotoxicity; allergic reactions; tumor lysis syndrome; thyroid disorders; neuropathy; increased risk of second primary malignancies.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events (exacerbation of pre-existing psychosis, manic episodes, aggressive behavior),Seizures (may lower seizure threshold),Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk, especially with concomitant serotonergic drugs,Long-term growth suppression in children
Pregnancy; hypersensitivity to lenalidomide; concomitant use with live vaccines; breastfeeding not recommended.
Hypersensitivity to amphetamine or other components,Concurrent use or within 14 days of MAOIs (risk of hypertensive crisis),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (symptomatic, moderate to severe hypertension, advanced arteriosclerosis, structural cardiac abnormalities)
Avoid grapefruit, grapefruit juice, and Seville oranges (including marmalade) as they inhibit CYP3A4 and may increase lenalidomide exposure. No other significant food interactions. Take capsules with water; do not crush or chew.
Avoid high-fat meals close to dosing as they may delay absorption. Acidic foods (e.g., citrus, cola, vitamin C) can decrease absorption; take with non-acidic fluids. Avoid alcohol and caffeine-containing products.
Lenalidomide is a thalidomide analogue; it is teratogenic in humans. Pregnancy category X. In the first trimester, there is a high risk of severe birth defects (e.g., limb defects, cardiac anomalies) and fetal death. No adequate studies in second or third trimester, but risk persists throughout pregnancy. Contraindicated in pregnancy.
First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/third trimesters: Risk of fetal growth restriction, preterm delivery, neonatal withdrawal (irritability, feeding problems), and persistent pulmonary hypertension.
No data on lenalidomide in human milk; however, due to potential for serious adverse effects in nursing infants (including neutropenia and thrombocytopenia), breastfeeding is contraindicated during therapy and for at least 1 week after last dose. M/P ratio unknown.
Present in breast milk; M/P ratio approximately 2.5-7.5. Potential for infant stimulation, insomnia, reduced weight gain. Caution recommended; consider delaying breastfeeding until 1-2 hours after dose.
Lenalidomide is contraindicated in pregnancy; no dose adjustments are recommended because use is prohibited. No pharmacokinetic studies in pregnancy; however, physiological changes (e.g., increased volume of distribution, renal clearance) may alter drug levels, but given teratogenicity, dosing is not applicable.
Pregnancy reduces amphetamine plasma concentrations by 15-50% during second/third trimesters due to increased clearance. Dose may need upward titration to maintain clinical effect, with careful monitoring for adverse effects.
Lenalidomide is an immunomodulatory drug (IMi D) with anti-angiogenic and anti-proliferative properties. It requires risk evaluation and mitigation strategy (REMS) due to teratogenicity. Monitor for thromboembolic events (DVT/PE) especially when combined with dexamethasone. Consider dose adjustment for renal impairment (Cr Cl < 60 m L/min). Baseline and periodic monitoring of CBC, thyroid function, and liver enzymes is essential. May cause tumor lysis syndrome in high tumor burden patients; ensure hydration and prophylaxis.
Adderall 15 mg (amphetamine/dextroamphetamine) is an immediate-release formulation; onset 30-60 min, duration 4-6 hours. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Consider drug holidays to assess need and reduce tolerance. Do not use with MAOIs or within 14 days of MAOI therapy. Risk of abuse and dependence; screen for substance use history. Use with caution in patients with pre-existing cardiovascular disease or psychiatric disorders.
Do not take lenalidomide if you are pregnant, breastfeeding, or planning to become pregnant; use two reliable forms of contraception during treatment and for 4 weeks after stopping.,Do not donate blood or sperm while taking lenalidomide and for 4 weeks after discontinuation.,Report any symptoms of blood clots (swelling, pain, redness in leg, sudden chest pain, shortness of breath) or signs of infection (fever, chills) immediately.,Take lenalidomide exactly as prescribed, usually once daily with a glass of water; do not break, chew, or open capsules.,Avoid grapefruit, grapefruit juice, and Seville oranges as they may affect drug metabolism.,Keep all appointments for blood tests to monitor for low blood cell counts and other side effects.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose in the morning; if prescribed a second dose, take it by early afternoon to avoid sleep problems.,Swallow tablet whole; do not crush or chew.,Avoid alcohol and caffeine; may increase side effects like nervousness and rapid heartbeat.,Report chest pain, palpitations, shortness of breath, or fainting immediately.,Inform your doctor of all medications, including over-the-counter and herbal products, especially antidepressants.,May cause weight loss; monitor growth in children.,Can impair ability to drive or operate machinery until you know how it affects you.,Store at room temperature away from moisture and heat.,Do not abruptly stop; taper under medical supervision to avoid withdrawal.
"The combination of lenalidomide and leflunomide may result in additive hematologic toxicity, particularly bone marrow suppression, due to overlapping mechanisms that impair hematopoietic cell proliferation and survival. Leflunomide, via its active metabolite teriflunomide, inhibits dihydroorotate dehydrogenase (DHODH) and suppresses pyrimidine synthesis in rapidly dividing cells, while lenalidomide modulates the ubiquitin E3 ligase cereblon, leading to altered cytokine production and direct antineoplastic effects. Clinically, patients may experience increased risks of severe neutropenia, thrombocytopenia, and anemia, potentially requiring dose reductions, growth factor support, or discontinuation of one agent."
"Digoxin, a cardiac glycoside, is a P-glycoprotein (P-gp) substrate. Lenalidomide, an immunomodulatory drug, can inhibit P-gp activity, leading to increased intestinal absorption and reduced renal clearance of digoxin. This interaction may cause elevated serum digoxin levels, increasing the risk of digoxin toxicity (e.g., arrhythmias, nausea, visual disturbances)."
"Lenalidomide, an immunomodulatory drug, increases the thrombogenic potential of Mestranol, an estrogen component of oral contraceptives, by enhancing platelet aggregation and endothelial activation. This combined prothrombotic effect elevates the risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Patients, especially those with additional risk factors, require careful monitoring for signs of thrombosis."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LENALIDOMIDE vs ADDERALL 15, answered by our medical review team.
LENALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.. ADDERALL 15 is a CNS Stimulant that works by Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LENALIDOMIDE and ADDERALL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LENALIDOMIDE is: 10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.. The standard adult dose of ADDERALL 15 is: 10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LENALIDOMIDE and ADDERALL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LENALIDOMIDE is classified as Category C. Lenalidomide is a thalidomide analogue; it is teratogenic in humans. Pregnancy category X. In the first trimester, there is a high risk of severe birth defects (e.g., limb defects,. ADDERALL 15 is classified as Category C. First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.